Oxford Cannabinoid Technologies Holdings plc announced that the final dose of its lead pharmaceutical drug compound, OCT461201, has been successfully administered, as part of its Phase I clinical trial, with no drug adverse effects observed. The trial is being conducted in the UK in healthy volunteers by Simbec Research Limited, part of Simbec-Orion Group Ltd, using a single ascending dose protocol. The final dose was successfully administered on 20 September 2023, in line with the Company's previously announced timeframe.

The trial's principal objective is to demonstrate the safety and tolerability of OCT461201, whilst also providing pivotal information on its pharmacokinetic profile, to confirm its value as a potential drug. The Company expects to report results by 16 October 2023.